株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:非アルコール性脂肪性肝炎 (NASH) の疫学予測

EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025

発行 GlobalData 商品コード 278796
出版日 ページ情報 英文 56 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.01円で換算しております。
Back to Top
EpiCast Report:非アルコール性脂肪性肝炎 (NASH) の疫学予測 EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025
出版日: 2016年12月01日 ページ情報: 英文 56 Pages
概要

世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本) における非アルコール性脂肪性肝炎 (NASH) の総患者数は、2015年の60,325,647人から、2025年には64,273,379人まで増加する (年間平均増加率0.65%) と予測されています。

当レポートでは、世界の主要7ヶ国における非アルコール性脂肪性肝炎 (NASH) について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 疫学

  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 利用しなかった情報源
  • NASHの疫学予測
    • 患者総数
    • 患者総数 (年齢別)
    • 患者総数 (性別)
    • 有病率 (年齢調整)
    • 診断された患者数
    • 診断された患者数:併存疾患別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第3章 付録

図表

目次
Product Code: GDHCER139-16

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2014). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2014). However, symptoms including fatigue, weight loss, and weakness emerge once the disease has progressed to a more advanced stage, like cirrhosis. NASH is suspected if elevated liver enzymes are detected during routine blood panels, but it is only definitively diagnosed when a liver biopsy is performed (NIDDK, 2014).

Both NASH and non-alcoholic fatty liver (NAFL) are histologically categorized under the umbrella of non-alcoholic fatty liver disease (NAFLD). NAFL is defined as the presence of a fatty liver with no evidence of hepatocellular injury or fibrosis, whereas NASH is defined as the presence of fatty liver and inflammation with evidence of hepatocyte injury (in the form of ballooning), with or without fibrosis.

Epidemiologists forecast that the total prevalent cases of NASH in the 7MM will grow by 0.65% per year over the next 10 years, from 60,325,647 cases in 2015, to 64,273,379 cases in 2025. In the 7MM, the US will have the highest number of total prevalent cases throughout the forecast period, accounting for 56.85% of all total prevalent cases in the 7MM in 2015. When analyzing the individual markets, more than 85.00% of the total prevalent cases of NASH occurred in ages 20 years and older and more cases occurred in men compared with women.

7MM will see an increase in the diagnosed prevalent cases of NASH from 16,952,459 cases in 2015 to 31,000,983 cases in 2025, at the rate of 8.29%. Diagnosed prevalent cases are forecast to increase faster than total prevalent cases due to expected increase in diagnosis rate, as indicated by primary research. Among the diagnosed prevalent cases of NASH, obesity is the most common comorbidity, where 78.68% of the NASH cases also are obese.

The report “EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025” provide an overview of the risk factors and global trends of NASH in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases (both diagnosed and undiagnosed) of NASH segmented by age and sex. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of NASH, which are further segmented by comorbid disorders, including obesity, diabetes mellitus type 2 (T2D), hyperlipidemia, and hypertension in these markets.

Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 6
  • 1.2 List of Figures 7

2 Epidemiology 8

  • 2.1 Risk Factors and Comorbidities 8
  • 2.2 Global Trends 10
    • 2.2.1 US 11
    • 2.2.2 5EU 12
    • 2.2.3 Japan 13
  • 2.3 Forecast Methodology 14
    • 2.3.1 Sources Used Tables 15
    • 2.3.2 Forecast Assumptions and Methods 18
    • 2.3.3 Sources Not Used 27
  • 2.4 Epidemiological Forecast for NASH (2015-2025) 28
    • 2.4.1 Total Prevalent Cases of NASH 28
    • 2.4.2 Age-Specific Total Prevalent Cases of NASH 30
    • 2.4.3 Sex-Specific Total Prevalent Cases of NASH 32
    • 2.4.4 Age-Standardized Prevalence of NASH 34
    • 2.4.5 Diagnosed Prevalent Cases of NASH 35
    • 2.4.6 Diagnosed Prevalent Cases of NASH by Comorbid Disorder 37
  • 2.5 Discussion 39
    • 2.5.1 Epidemiological Forecast Insight 39
    • 2.5.2 Limitations of the Analysis 40
    • 2.5.3 Strengths of the Analysis 42

3 Appendix 43

  • 3.1 Bibliography 43
  • 3.2 Physicians and Specialists Included in this Study 50
  • 3.3 About the Authors 51
    • 3.3.1 Epidemiologists 51
    • 3.3.2 Reviewers 51
    • 3.3.3 Global Director of Therapy Analysis and Epidemiology 53
  • 3.4 About GlobalData 54
  • 3.5 About EpiCast 54
  • 3.6 Disclaimer 55

List of Tables

  • Table 1: Risk Factors and Comorbidities for NASH 9
  • Table 2: 7MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of NASH 15
  • Table 3: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of NASH 16
  • Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of NASH by Comorbid Disorder 17
  • Table 5: 7MM, Total Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Select Years, 2015-2025 29
  • Table 6: 7MM, Age-Specific Total Prevalent Cases of NASH, Both Sexes, N (Row %), 2015 31
  • Table 7: 7MM, Sex-Specific Total Prevalent Cases of NASH, Ages ≥4 Years, N (Row %), 2015 33
  • Table 8: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Select Years, 2015-2025 36
  • Table 9: 7MM, Diagnosed Prevalent Cases of NASH, by Comorbid Disorder, Ages ≥4 Years, N (Row %), 2015 38
  • Table 10: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 50

List of Figures

  • Figure 1: 5EU, Total Prevalence of NAFLD and Obesity (%), Ages ≥20 Years, Both Sexes 13
  • Figure 2: 7MM, Total Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Selected Years, 2015-2025 30
  • Figure 3: 7MM, Age-Specific Total Prevalent Cases of NASH, Both Sexes, 2015 32
  • Figure 4: 7MM, Sex-Specific Total Prevalent Cases of NASH, Ages ≥4 Years, 2015 34
  • Figure 5: 7MM, Age-Standardized Total Prevalence of NASH, Ages ≥4 Years, 2015 35
  • Figure 6: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, Ages ≥4 Years, Selected Years, 2015-2025 37
  • Figure 7: 7MM, Diagnosed Prevalent Cases of NASH, by Comorbid Disorder, Ages ≥4 Years, N, 2015 38
Back to Top